|Celtaxsys has completed its Phase 2b trial assessing the safety and effectiveness of acebilustat (formerly CTX-4430) for cystic fibrosis (CF), with the company announcing the last visit of the last enrolled patient. Details of the trial, supported by the Cystic Fibrosis Foundation, will be presented at the upcoming 41st European Cystic Fibrosis Society Conference June 6-9 in Belgrade, […]|
The post #ECFS2018 — Celtaxsys Completes Phase 2b Trial Assessing Acebilustat in Cystic Fibrosis Patients appeared first on Cystic Fibrosis News Today.
Hubble Makes Unexpected Dark Matter Discovery
Hace 2 horas